New Rectal Cancer Immunotherapy May Let Patients Skip Surgery

A new Rectal Cancer Immunotherapy has won fast-tracked federal approval, and it could spare some patients the grueling standard treatment of chemotherapy, radiation and major surgery. The United States Food and Drug Administration granted accelerated approval to the immunotherapy Jemperli on October 19, 2026, for adults with stage two or stage three locally advanced rectal cancer whose tumors carry a specific genetic marker.

To qualify, patients must have previously untreated disease and tumors that are mismatch repair deficient or microsatellite instability-high, as shown by an authorized test. Published estimates suggest roughly three percent of locally advanced rectal cancers carry that signature. For those patients, the drug is used on its own, offering a treatment path that sidesteps the operating room entirely.

The approval rests on results from a clinical trial called AZUR-1, which enrolled one hundred fifty-four patients. Investigator assessments showed that about two-thirds of evaluable participants achieved a sustained complete response lasting twelve months. In an exploratory analysis, roughly three in four participants had no detectable cancer a year or more after treatment, and no responders had seen their disease return after a median follow-up of more than two years.

Full results from the interim analysis are scheduled to be presented as a late-breaking abstract at the ESMO Congress in Madrid on October 25, 2026, according to a company announcement from GSK released the same day the approval was announced.

Who qualifies for the new treatment

The authorization covers adults with stage two or stage three locally advanced rectal cancer, meaning the cancer has grown into nearby tissue or reached nearby lymph nodes but has not spread to distant organs. Eligibility hinges on a genetic feature: tumors must be mismatch repair deficient or microsatellite instability-high, determined by an FDA-authorized test.

That narrows the field considerably. Only about three in one hundred locally advanced rectal cancers carry the marker, so this is not a broad replacement for conventional treatment. Still, for the small group that qualifies, the shift is profound. The drug is given intravenously every three weeks for nine cycles unless unacceptable side effects or disease progression occur, according to the Oncology Nursing Society's summary of the approval.

Patients who achieved a complete response at early check-ins entered a monitoring phase instead of heading to surgery, with scans and endoscopies every four months for the first two years and every six months after that. Those whose cancer did not fully respond were evaluated for standard care.

Why avoiding surgery matters so much

The usual course for locally advanced rectal cancer is chemotherapy and radiation first, followed by surgery. Those treatments can leave lasting marks: they can affect bowel, urinary and sexual function, as well as fertility. Surgery carries risks of serious complications, including poor healing and leaks where the bowel is reconnected, and in some patients a permanent colostomy.

An immunotherapy that makes tumors vanish without any of that represents a genuine change in the calculus. As Acting FDA Commissioner Kyle Diamantas said in the agency's announcement, completing the review nearly four months ahead of schedule means some patients who might otherwise be preparing for surgery, radiation or chemotherapy may now have a different conversation with their doctor. The application for the Rectal Cancer Immunotherapy carried Fast Track and Breakthrough Therapy designations, plus a National Priority Voucher, which moved the decision ahead of the February 2027 deadline.

This is the first immunotherapy authorized for this use, and it follows a pattern of immune-based drugs rewriting expectations for cancers with this genetic signature. Read about other recent cancer research, including how weight-loss surgery may lower cancer risk at any age, for a sense of how fast oncology is moving.

What still needs answering

An accelerated approval is not the same as a final verdict. The authorization is based on response rates rather than long-term survival data, and the trial data continue to mature. Anyone eligible will need close, ongoing surveillance even if surgery is avoided, because the monitoring schedule itself is part of the deal.

It is also worth keeping perspective on scope. Colorectal cancers are rising in younger adults, a trend worth watching even as this approval targets a narrow slice of cases. For broader health habits that support long-term resilience, see reporting on how a strong social life may keep aging brains sharper.

The bottom line for patients and families: if you or someone you love is facing a rectal cancer diagnosis, ask the oncologist whether the tumor has been tested for this genetic marker. The test decides eligibility, and for the few who qualify, the treatment conversation in 2026 looks very different than it did a year ago.